First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Mengxing You und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Translational Medicine Research Project of Beijing Cancer Prevention and Treatment Research Association, Medical Oncology Innovation Team of Cancer Hospital Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Background
Optimal treatment for driver gene‐negative non‐small cell lung cancer ( NSCLC ) with brain metastases ( BM ) remains unclear, particularly regarding immune checkpoint inhibitor ( ICI )‐based combinations and local BM therapy. Predictive biomarkers for intracranial efficacy are also undefined.
Methods
This retrospective study analyzed driver gene‐negative NSCLC patients with BM treated with first‐line ICI ‐based systemic therapy ( ICI plus chemotherapy [ ICI + CT ] or ICI + CT plus bevacizumab [ ICI + CT + Bev]) from June 2019 to June 2024. The intracranial progression‐free survival ( icPFS ), progression‐free survival ( PFS ), and overall survival ( OS ) were compared between treatment groups and by BM local therapy. The PD ‐ L1 tumor proportion score ( TPS ) expression was evaluated for correlation with intracranial efficacy.
Results
A total of 36 patients were enrolled in the study. The intracranial objective response rate ( icORR ) was 70.6% ( ICI + CT ) versus 78.6% ( ICI + CT + Bev) ( p = 0.689), with no significant differences in icPFS , PFS , or OS between the two different first‐line systemic regimens (all p > 0.05). Local BM therapy ( n = 18) did not improve icPFS and OS (all p > 0.05). Extracranial PD ‐ L1 ( TPS ≥ 50%, n = 13) correlated with superior icPFS , PFS , and OS (all p < 0.05) versus PD ‐ L1 TPS < 50%. Multivariate analysis confirmed PD ‐ L1 ≥ 50% as an independent prognostic factor ( HR = 0.155; 95% CI , 0.025–0.939; p = 0.042).
Conclusions
Adding bevacizumab to first‐line ICI ‐chemotherapy did not enhance survival outcomes. Local treatment for BM did not provide additional survival advantages when combined with first‐line ICI ‐based systemic therapy. Extracranial PD ‐ L1 TPS ≥ 50% predicted improved intracranial efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Puyuan Xing, Junling Li
Förderung
- Translational Medicine Research Project of Beijing Cancer Prevention and Treatment Research Association
- Medical Oncology Innovation Team of Cancer Hospital Chinese Academy of Medical Sciences
Zitieren
APA
You, M., Wu, L., Liu, J., Yuan, H., Wang, Z., Hao, X., Xing, P., & Li, J. (2025). First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70095
Vancouver
You M, Wu L, Liu J, Yuan H, Wang Z, Hao X, et al. First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70095
BibTeX
@article{You2025,
author = {You, Mengxing and Wu, Lige and Liu, Jiayu and Yuan, Hanqi and Wang, Zihe and Hao, Xuezhi and Xing, Puyuan and Li, Junling},
title = {First‐Line Immune‐Combination Therapy for Driver Gene‐Negative NSCLC With Brain Metastases: Real‐World Outcomes},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70095}
}
EUVIMED